Slide 1: Cover letter to stock exchanges: Presentation of Q2 FY23 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com November 15, 2022 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corpo
Slide 2: Q2 FY23 Earnings Call
Q2 FY23 Earnings Call November 15, 2022 B I O C O N L I M I T E D 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Tribute to John Shaw
Tribute to John Shaw B I O C O N L I M I T E D 33
Slide 5: John McCallum Marshall Shaw
John McCallum Marshall Shaw (April 12, 1949 - Oct 24, 2022) A Scotsman by Birth, an Indian at Heart & A Global Citizen • Former Vice Chairman of Biocon Group served as a key member of the Board and the management team since 1999 • Contributed majorly to the transformation of Biocon into a globally r
Slide 6: Q2 FY23 Earnings Call
Q2 FY23 Earnings Call B I O C O N L I M I T E D 55
Slide 7: Opening Remarks
Opening Remarks Slowdown in the global economy India uniquely poised for significant export-led growth Generics and biosimilars are a necessity Biocon improves its ESG score B I O C O N L I M I T E D 6
Slide 8: Board Update
Board Update B I O C O N L I M I T E D 77
Slide 9: Board Update
Board Update Peter Bain joins the Biocon Limited Board as Additional Independent Director • Holds a bachelor’s degree in Science (Combined honors in Zoology and Physiology) from the University of Sheffield, United Kingdom. • Global experience in strategic and operational leadership roles of over 30
Slide 10: Viatris Acquisition Update
Viatris Acquisition Update B I O C O N L I M I T E D 99
Slide 11: Biosimilars: Viatris acquisition update
Biosimilars : Viatris acquisition update Acquisition of Viatris’ biosimilar business expected to close shortly BBL has secured $1.2 bn in debt, balance amount to be funded through equity infusion. EQUITY INFUSION IN BBL SILS $150m Biocon Ltd $650m On closing of the Viatris and Serum transactions, Bi
Slide 12: Preparing for integration and commercial success
Preparing for integration and commercial success Matthew Erick Stephen Fecho Jr, Stephen Manzano Chief Commercial Officer - Global Head, Supply Chain General Counsel, Advanced Advanced Markets Management Markets 20+ years experience at Mylan (Viatris), 25+ years experience at Merck & Co, 20+ years o
Slide 13: Q2 FY23 Financial Highlights
Q2 FY23 Financial Highlights B I O C O N L I M I T E D 12 12
Slide 14: Financial Highlights: Q2 FY23
Financial Highlights: Q2 FY23 Q2 FY23 Q2 FY22 Revenue +23% ₹2,384 Cr ₹1,945 Cr Biosimilars +34% | Research +26% | Generics +18% Adjusted for: Core EBITDA* +34% ₹816 Cr ₹609 Cr Dilution gain Bicara of ₹33 Cr in Q2 FY23 Adagio MTM gain ₹55 Cr gain in Q2 FY22 % margin 35% 33% Gross R&D spend at ₹252 Cr
Slide 15: Exceptional Items: Q2 FY23
Exceptional Items: Q2 FY23 Q2 FY23 Q2 FY22 Exceptional items during Q2 FY23: Net Profit ₹168 Cr ₹188 Cr (before exceptional charge) • MAT credit balance charge of ₹107 Crores on adoption of new tax regime of 25%. This move helps Biocon reduce tax outflow and P&L charge on a go-forward basis. Excepti
Slide 16: Q2 FY23 Generics
Q2 FY23 Generics B I O C O N L I M I T E D 15 15
Slide 17: Generics: Q2 FY23 update
Generics: Q2 FY23 update KEY HIGHLIGHTS Q2 FY23 Q2 FY22 Strong YoY growth both in API & generic formulations Revenue ₹623Cr ₹530Cr +18% Sitagliptin and Vildagliptin API launches in EU Generic Formulations - Approvals in EU & MoW markets to aid geographical expansion Profit Before Tax (PBT) ₹54Cr ₹50
Slide 18: Q2 FY23 Biosimilars
Q2 FY23 Biosimilars B I O C O N L I M I T E D 17 17
Slide 19: Biosimilars: Q2 FY23 Update
Biosimilars: Q2 FY23 Update KEY HIGHLIGHTS Q2 FY23 Q2 FY22 Year-on-year revenue growth of 34%, reflecting the growth of insulin Revenue Glargine in US ₹997Cr ₹743Cr +34% Core EBITDA margin benefitted from rupee depreciation and accrual of Performance Linked Incentives (PLI) benefits Core EBITDA* Pro
Slide 20: Q2 FY23 Novels
Q2 FY23 Novels B I O C O N L I M I T E D 19 19
Slide 21: Novels: Q2 FY23 Update
Novels : Q2 FY23 Update KEY HIGHLIGHTS Itolizumab: Equillium announced encouraging interim data from EQUALISE study in Lupus Nephritis Application to conduct Phase II Clinical Trial with Itolizumab for Ulcerative Colitis approved by DCGI Bicara# : Continued progress in BCA 101 #In Q4FY21, Biocon ced
Slide 22: Q2 FY23 Research Services
Q2 FY23 Research Services B I O C O N L I M I T E D 21 21
Slide 23: Research Services: Q2 FY23 Update
Research Services: Q2 FY23 Update KEY HIGHLIGHTS Q2 FY23 Q2 FY22 Positive performance across all divisions. Revenue from operations ₹768Cr ₹610Cr +26% Sustained growth in research divisions - Discovery Services, including Synvent#, and the Dedicated Centres. Growth in Development Services led by exi
Slide 24: Concluding Remarks
Concluding Remarks B I O C O N L I M I T E D 23 23
Slide 25: Q&A
Q&A B I O C O N L I M I T E D 24 24